Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm

被引:93
作者
Hanna, WM [1 ]
Kwok, K [1 ]
机构
[1] Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON M4N 3M5, Canada
关键词
HER2; testing; CISH; FISH; concordance; HER2 testing algorithm;
D O I
10.1038/modpathol.3800555
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Assessment of human epidermal growth factor receptor-2 status is standard practice in women with breast cancer. Most laboratories use immunohistochemistry as a screening test, with equivocal results confirmed by fluorescence in-situ hybridization (FISH). Chromogenic in-situ hybridization (CISH) is a relatively new method for detection of gene amplification using a peroxidase reaction, which can be viewed using a standard light microscope. This study was undertaken to validate CISH as a method for assessing human epidermal growth factor receptor-2 gene amplification. The gene amplification status of human epidermal growth factor receptor-2 immunohistochemistry negative (0/1 +, n=69; Group 1), immunohistochemistry positive (3+, n=50; Group 2) and equivocal tumor samples (2+, n=135; Group 3) was evaluated by FISH and CISH, and the concordance between FISH and CISH results calculated. In Group 1, 67/69 cases did not show amplification by CISH and 69/69 showed no amplification by FISH. Two cases were discordant; therefore, fluorescence/CISH concordance was 97%. In Group 2, 46/50 cases were amplified by FISH and 47/50 cases were amplified by CISH; three cases were not amplified by either method (immunohistochemistry false-positives). Only one case showed discordant FISH and CISH results, making the fluorescence/CISH concordance 98%. In Group 3, 89/135 cases were not amplified and 37/135 were amplified by both methods. Nine cases were discordant, giving a fluorescence/CISH concordance of 93%. The discordant cases were those with very low or borderline amplification with FISH. The high level of concordance between FISH and CISH seen in this study suggests that CISH may be a viable alternative to FISH for use in the human epidermal growth factor receptor-2 testing algorithm.
引用
收藏
页码:481 / 487
页数:7
相关论文
共 50 条
  • [41] Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma
    Zhao, JX
    Wu, RN
    Au, A
    Marquez, A
    Yu, YB
    Shi, ZR
    MODERN PATHOLOGY, 2002, 15 (06) : 657 - 665
  • [42] HER2 Dual In Situ Hybridization Correlations and Cautions
    Troxell, Megan
    Sibley, Richard K.
    West, Robert B.
    Bean, Gregory R.
    Allison, Kimberly H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (12) : 1525 - 1534
  • [43] Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization
    Layfield, Lester J.
    Willmore-Payne, Carlynn
    Isom, Gary
    Holden, Joseph A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (06) : 562 - 567
  • [44] Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization:: Comparison with immunohistochemistry
    Kounelis, S
    Kapranos, N
    Malamos, N
    Kouri-Bairaktari, E
    ANTICANCER RESEARCH, 2005, 25 (2A) : 939 - 946
  • [45] Feasibility of Haralick's Texture Features for the Classification of Chromogenic In-situ Hybridization Images
    Pavlov, Stoyan
    Momcheva, Galina
    Burlakova, Pavlina
    Atanasov, Simeon
    Stoyanov, Dimo
    Ivanov, Martin
    Tonchev, Anton
    PROCEEDINGS OF THE 2020 INTERNATIONAL CONFERENCE ON BIOMEDICAL INNOVATIONS AND APPLICATIONS (BIA 2020), 2020, : 65 - 68
  • [46] HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies
    Robertson, Scott A.
    Cimino-Mathews, Ashley
    Cornish, Toby C.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (01) : 35 - 39
  • [47] Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer
    Furrer, Daniela
    Jacob, Simon
    Caron, Chantal
    Sanschagrin, Francois
    Provencher, Louise
    Diorio, Caroline
    ANTICANCER RESEARCH, 2017, 37 (06) : 3323 - 3329
  • [48] Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer:: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
    Gong, Y
    Gilcrease, M
    Sneige, N
    MODERN PATHOLOGY, 2005, 18 (08) : 1015 - 1021
  • [49] Bright-Field HER2 Dual In Situ Hybridization (DISH) Assay vs Fluorescence In Situ Hybridization (FISH) Focused Study of Immunohistochemical 2+Cases
    Gao, Faye F.
    Dabbs, David J.
    Cooper, Kristine L.
    Bhargava, Rohit
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (01) : 102 - 110
  • [50] HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce, Francesca
    Bufo, Pantaleo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (03) : 385 - 398